Welcome to the e-CCO Library!

DOP17: Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with Ulcerative Colitis: Results from a prospective cohort study
Year: 2022
Source: ECCO'22
Authors: Lenfant, M.(1,2);Verstockt, B.(1,2);Sabino, J.(1,2);Vermeire, S.(1,2);Ferrante, M.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
DOP17: HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Margalida Calafat Sard
Created: Friday, 14 July 2023, 2:22 PM
DOP17: HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Calafat Sard, M.(1,2)*;Súria, C.(3);Mesonero, F.(4);de Francisco, R.(5);Yagüe Caballero, C.(6);de la Peña, L.(7);Hernández-Camba, A.(8);Marcè, A.(9);Gallego, B.(10);Martín-Vicente, N.(11);Rivero, M.(12); Iborra, M.(13);Guerra, I.(14); Carrillo-Palau, M.(15);Madero, L.(16);Burgueño, B.(17); Montfort, D.(18);Torres, G.(19);Teller, M.(20);Ferrer Rosique, J.Á.(21);Vega Villaamil, P.(22);Roig, C.(23);Ponferrada, Á.(24); Betoré Glaría, E.(25);Zabana, Y.(2,26); P. Gisbert, J.(2,27);Alcaide, N.(28);Camps, B.(29);Legido, J.(30);González Vivo, M.(31);Bosca-Watts, M.M.(32);Pérez-Martínez, I.(5);Casas Deza, D.(6,33);Guardiola, J.(7);Arranz Hernández, L.(8); Navarro, M.(34);Gomollon, F.(2,10);Cañete, F.(1,2); Mañosa, M.(1,2);Domènech, E.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP17: In high-risk Crohn’s Disease patients, anastomosis configuration types have similar rates of endoscopic recurrence
Year: 2021
Source: ECCO'21 Virtual
Authors: Bachour, S.(1);Shah, R.(1);Lyu, R.(2);Rieder, F.(1);Cohen, B.(1);Qazi, T.(1);Lashner, B.(1);Lipman, J.(3);Regueiro, M.(1);Lightner, A.(3);Holubar, S.(3);Click, B.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP17: Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gros, Beatriz
Created: Tuesday, 30 April 2024, 5:03 PM
DOP18 Impact of adherence to anti-tumour necrosis factor therapy on clinical outcomes in Crohn’s disease: A nationwide population-based study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.J. Park1, H. Koo2, Y. Park1, S.J. Park1, T.I. Kim1, W.H. Kim1, J.H. Cheon1, E.H. Han2

Created: Thursday, 30 January 2020, 10:12 AM
DOP18: Advanced optical diagnosis technology for assessment of endoscopic and histological remission in Ulcerative Colitis: A systematic review and meta-analysis
Year: 2022
Source: ECCO'22
Authors: Nardone, O.M.(1);Snir , Y.(2,3);Hodson, J.(4);Cannatelli, R.(1);Labarile, N.(1);Siau, K.(1,5);Hassan, C.(6);Yanai, H.(2,3);Dotan, I.(2,3);Ghosh, S.(1,7,8,9);Iacucci, M.(1,8,9);
Created: Friday, 11 February 2022, 3:52 PM
DOP18: Brain structural correlates of fatigue in active and quiescent Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Thomann, A.(1)*;Schmitgen, M.(2);Szabo, K.(3);Ebert, M.(4);Reindl, W.(4);Wolf, C.(5);
Created: Friday, 14 July 2023, 10:43 AM
DOP18: Brain structural correlates of fatigue in active and quiescent Crohn’s Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Anne Thomann
Created: Friday, 14 July 2023, 2:22 PM
DOP18: Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Peyrin-Biroulet, Laurent
Created: Tuesday, 30 April 2024, 5:03 PM
DOP18: Impact of adherence to anti- tumor necrosis factor therapy on clinical outcomes in Crohn's Disease: A nationwide population-based study
Year: 2020
Source: ECCO'20 Vienna
Authors: Jae Jun Park
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Gillian Tannahill
Created: Tuesday, 28 May 2019, 3:32 PM
Immunology
Files: 1
DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine production
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Vossenkamper1, K. Foster2, K. Nevin2, G. Tannahill*2, S. Flint2, T. T. McDonald1

Created: Friday, 22 February 2019, 9:41 AM
DOP18: UCEIS is associated with PRO2, partial Mayo and SCCAI remission in UC: Final results from a prospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: Golovics, P.(1);Gonczi, L.(2);Reinglas, J.(3);Verdon, C.(3);Pundir, S.(3);Afif, W.(3);Wild, G.(3);Bitton, A.(3);Bessissow, T.(3);Lakatos, P.L.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Cohen1, H. Chang2, J.R. Jason Rogers1, S. Garg1, D. Lawrence3, F. Fasihuddin1, T. Lissoos4, A. Atreja5

Created: Thursday, 30 January 2020, 10:12 AM